Home' Australian Pharmacist : Australian Pharmacist September 2014 Contents Only Panadol® Osteo has
unique bi-layer technology.1
Proven relief from
osteoarthritis pain for
with each dose.1
GSK1176_L - 1 2014- 08- 01T10: 58: 10+10: 00
Your customers with osteoarthritis
Osteoarthritis (OA) is the most prevalent form of
chronic arthritis, affecting more than 1.3 million
It primarily affects the joints of the
knees, hips, spine, hands and toes.
experienced by customers with OA include joint
stiffness, reduced mobility, swelling, and tenderness,
but for most people, the major complaint is pain.
While there is no cure for OA,
recommended by guidelines as the first-line
treatment for the management of OA pain.
Only Panadol® Osteo supports your customers
Like many other long-term conditions, empowering
people to self-manage their pain can be beneficial.
However, in a busy pharmacy, it can be difficult to
provide customers with the skills they require to
self-manage their OA. Only Panadol® Osteo helps
customers take control of their OA with a comprehensive
Support Programme. By registering in the Programme
(www.panadol.com.au/osteo), your Panadol® Osteo
customers receive regular emails, newsletters and
practical tips on how to stay healthy and active
when living with OA.
Recommend Panadol® Osteo in combination with
The aims of OA management are to optimise quality
of life by enhancing mobility and minimising pain.
Your customers can benefit from a comprehensive
OA management strategy that encompasses pain
relief with Panadol® Osteo in combination with
the recognised benefits of non-pharmacological
interventions, such as weight reduction and exercise.
Recommend Panadol® Osteo for your customers
with OA – the No. 1 most prescribed medicine
in Australia, for relief of OA pain.
Simplicity of 3-times daily dosing with Panadol®
Osteo may aid compliance11
Just 3 daily doses of Panadol® Osteo provides effective
pain relief for up to 24 hours. The convenience and
simplicity of 3-times daily dosing with Panadol® Osteo
may also aid compliance with treatment (compared with
4-times daily dosing for immediate-release paracetamol).11
Only Panadol® Osteo has patented bi-layer
technology to relieve OA pain for up to 8 hours1
of paracetamol for rapid
onset of action9
of paracetamol for up to
8 hours of pain relief 1,9,10
Please review Approved Product Information (PI) for Panadol® Osteo before recommending.
The full PI is available from GlaxoSmithKline Consumer Healthcare on request (FREECALL: 1800 028 533). Panadol Osteo contains paracetamol 665 mg. Use: Symptomatic treatment of the persistent pain of
osteoarthritis. Contraindications: Hypersensitivity to any ingredient in the product; children under 12 years. Precautions: Should be administered with caution in patients with renal dysfunction or with hepatic
dysfunction. Adverse reactions: Reports of adverse reactions are rare, though dyspepsia, nausea and allergic reactions have been reported. Interactions: Anticoagulants. Dosage: Adults and children 12 years and
over: 2 tablets every 8 hours orally with water (maximum 6 tablets in 24 hours). PBS dispensing price (June 2012) for maximum quantity $16.64 (general patients) and $5.60 (concession).
References: 1. Panadol Osteo Approved Product Information. 2 . Australian Institute of Health and Welfare (AIHW). A picture of osteoarthritis in Australia, October 2007. Available at https://www.aihw.gov.au/arthritis-and-
musculoskeletal-conditions-publications/. Accessed on 30 January 2014. 3. Fitzcharles M-A et al. Drugs Aging 2010;27(6):471–90. 4. Australian Department of Health and Ageing. Osteoarthritis overview, May 2012.
Available at: www.health.gov.au (accessed June 2012). 5. Kean WF et al. Inflammopharmacology 2004;12(1):3–31. 6. Australian Therapeutic Guidelines: eTG complete [internet]. Melbourne: Therapeutic Guidelines
Limited 2010 Mar. Available at: www.tg.org.au. 7. Royal Australian College of General Practitioners (RAGCP). Guideline for the non-surgical management of hip and knee osteoarthritis 2009. Available at: www.racgp.org.
au/guidelines/osteoarthritis. Accessed on 30 January 2014. 8 . McKenzie S and Torkington A. Aust Fam Phys 2010;39(9):622–25. 9. Bacon TH et al. Australian Pain Society 2001:63−64, Abstract E2 (GSK sponsored).
10. Bacon TH et al. Br J Clin Pharmacol 2002;53(6):629−36 (GSK sponsored). 11. Claxton AJ et al. Clin Ther 2001;23(8):1296–310. 12 . Pharmaceutical Benefits Scheme (PBS). Expenditure and Prescriptions Twelve
Months to 30 June 2013. Available at: http://www.pbs.gov.au/info/statistics/expenditure-and-prescriptions-30 -06 -2013#Summary. Accessed on 1 April 2014.
PANADOL and package design elements are trade marks of the GlaxoSmithKline group of companies. GlaxoSmithKline Consumer Healthcare, 82 Hughes Avenue, Ermington NSW 2115. 07/14 GSK1176/UC. CHANZ/CHPAN/0252/14.
PBS Information. Restricted Benefit. Relief of persistent pain associated with osteoarthritis.
Refer to PBS Schedule for further information.
GSK1176_R - 2 2014- 08- 01T10: 51: 40+10: 00
Links Archive Australian Pharmacist October 2014 Australian Pharmacist August 2014 Navigation Previous Page Next Page